The FDA granted a breakthrough therapy designation to Novartis’s CTL019, a chimeric antigen receptor T cell immunotherapy, or CAR-T, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma that have failed two or more prior therapies.
During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells expressing a particular antigen.
The FDA accepted the company’s biologics license application filing and granted priority review for CTL019 in the treatment of pediatric and young adult patients with B-cell ALL. This is the second indication for which CTL019 has received this designation.
